Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-12-08
1997-07-01
Mullis, Jeffrey C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514406, A01N 4356
Patent
active
056439385
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/JP93/00762 filed Jun. 7, 1993.
TECHNICAL FIELD
The present invention relates to a new medical use of the pyrazolopyridine compound or a pharmaceutically acceptable salt thereof.
BACKGROUND ART
Some pyrazolopyridine compounds are known to be useful as psychostimulant, antihypertensive agent, remedy for renal insufficiency, diuretic, and the like (e.g. EP-0299209, EP-0379979, etc), but up to now it is not known that the pyrazolopyridine compound is useful for the prevention and/or the treatment of anemia.
DISCLOSURE OF INVENTION
The present invention relates to a new use of the pyrazolopyridine compound or a pharmaceutically acceptable salt thereof.
More particularly, it relates to the utility of the pyrazolopyridine compound for the prevention and/or the treatment of anemia in a human being or an animal.
Accordingly, one object of the present invention is to provide a pharmaceutical composition for the prevention and/or the treatment of anemia in a human being or an animal comprising, as an active ingredient, the pyrazolopyridine compound or a pharmaceutically acceptable salt thereof.
Another object of the present invention is to provide a method for the prevention and/or the treatment of anemia in a human being or an animal which comprises administering the pyrazolopyridine compound to a human being or an animal.
A further object of the present invention is to provide a use of the pyrazolopyridine compound for the manufacture of a medicament for the prevention and/or the treatment of anemia in a human being or an animal.
The inventors of the present invention have found the pyrazolopyridine compound or a pharmaceutically acceptable salt thereof has been useful for the prevention and/or treatment of anemia in a human being or an animal and have completed the present invention.
The inventors have also found the pyrazolopyridine compound of the present invention has increased the production of erythropoietin.
The pyrazolopyridine compound to be used in the present invention is shown by the following formula (I) : ##STR3## wherein R.sup.1 is lower alkyl, aryl which may have one or more suitable substituent(s) or a heterocyclic group, ##STR4## (wherein R.sup.4 is protected amino or hydroxy and suitable substituent(s) selected from the group consisting of lower alkyl, lower alkoxy(lower)alkyl, acyloxy(lower)alkyl, carboxy, protected carboxy and acyl(lower)alkyl, and substituent(s)); substituent(s);
Some of the compound (I) are known compounds and they are disclosed, for example, in EP-0299209, EP-0379979, EP-0467248, etc.
In the compound (I), the following compound (Ia) novel. ##STR5## wherein R.sub.a.sup.1 is aryl,
The compound. (Ia) or a salt thereof of the present invention can be prepared by the following reaction schemes. ##STR6## wherein R.sub.a.sup.1, R.sup.7 and A.sup.1 are each as defined above,
The reactions in above-mentioned Processes 1 to 4 can be carried out according to the procedures disclosed in Examples mentioned later in the present specification or the similar manners thereto.
It is to be noted that the object compound (I) may include the geometrical isomer(s) due to the double bond(s) and/or the stereo isomer(s) due to the asymmetric carbon atom(s). In this regard, one isomer can be converted to another according to a conventional manner in this field of the art.
Suitable pharmaceutically acceptable salts of the object compound (I) are conventional ones and include a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc), an ammonium salt, an organic base salt (e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc), an organic acid salt (e.g. acetate, trifluoroacetate, maleate, tartrate, fumalate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc), an inorganic acid salt (e.g. hydrochloride, hydrobromide, hydriodide, sulfate, phosphate, etc), a salt wit
REFERENCES:
patent: 5102878 (1992-04-01), Shiokawa et al.
patent: 5338743 (1994-08-01), Shiokawa et al.
patent: 5459031 (1995-10-01), Blumen et al.
Hanaoka Kaori
Kohno Yutaka
Nagatomi Itsuo
Fujisawa Pharmaceutical Co. Ltd.
Mullis Jeffrey C.
LandOfFree
Pyrazolopyridine compounds for the treatment of anemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolopyridine compounds for the treatment of anemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyridine compounds for the treatment of anemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-597597